Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Opiant Pharmaceuticals Inc's Business Segments
Opiant Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Opiant Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Grant0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 7 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of treatments for addictions and drug overdose. Formerly known as Lightlake Therapeutics Inc, the company changed its name to Opiant Pharmaceuticals in 2016. It is headquartered in Santa Monica, California.
The company's main area of expertise lies in the development of opioid antagonist treatments. These treatments work by blocking or reversing the effects of opioids, thus potentially reducing the risk of opioid overdose. Opiant Pharmaceuticals is committed to addressing the opioid crisis and reducing the harm caused by addiction.
Opiant Pharmaceuticals has an extensive research and development pipeline which includes both novel drug candidates and improved versions of existing therapies. The company conducts preclinical and clinical studies to assess the safety and efficacy of its product candidates. Opiant Pharmaceuticals consistently collaborates with renowned academic institutions and partners with government agencies to accelerate the development of its drug treatments.
One of the most prominent products developed by Opiant Pharmaceuticals is Narcan Nasal Spray, an opioid antagonist used for the emergency treatment of known or suspected opioid overdose. Narcan Nasal Spray is the first and only FDA-approved nasal spray version of naloxone, a medication that can rapidly reverse the effects of opioids and restore breathing to a person experiencing an opioid overdose. This product has been widely recognized as a significant contributor to opioid overdose reversal efforts, being highly effective and easy to use by both medical professionals and laypersons.
Beyond Narcan Nasal Spray, Opiant Pharmaceuticals is also developing other opioid antagonist products, such as intranasal nalmefene, a drug with a potentially longer duration of action compared to naloxone. The company aims to provide a comprehensive range of life-saving opioid overdose treatments to meet the diverse needs of patients and healthcare providers.
Furthermore, Opiant Pharmaceuticals has explored various novel drug candidates targeting substance use disorder and addiction. These include OPNT003, which is being developed for the treatment of binge eating disorder, and OPNT001, which is being investigated for reducing the craving and reward response associated with stimulant use disorder.
In addition to its research and development activities, Opiant Pharmaceuticals actively engages in collaborations with other organizations to advance its mission. The company has partnered with government agencies, including the National Institutes of Health (NIH), to secure funding and support for its research programs. It has also entered into licensing agreements with pharmaceutical companies to expand the availability of its products across geographies.
Overall, Opiant Pharmaceuticals Inc. is a leading specialty pharmaceutical company dedicated to developing innovative treatments for addiction and drug overdose. With a strong focus on opioid antagonist therapies, the company strives to make a positive impact in addressing the global opioid crisis and improving the lives of individuals affected by substance use disorders.
The company's main area of expertise lies in the development of opioid antagonist treatments. These treatments work by blocking or reversing the effects of opioids, thus potentially reducing the risk of opioid overdose. Opiant Pharmaceuticals is committed to addressing the opioid crisis and reducing the harm caused by addiction.
Opiant Pharmaceuticals has an extensive research and development pipeline which includes both novel drug candidates and improved versions of existing therapies. The company conducts preclinical and clinical studies to assess the safety and efficacy of its product candidates. Opiant Pharmaceuticals consistently collaborates with renowned academic institutions and partners with government agencies to accelerate the development of its drug treatments.
One of the most prominent products developed by Opiant Pharmaceuticals is Narcan Nasal Spray, an opioid antagonist used for the emergency treatment of known or suspected opioid overdose. Narcan Nasal Spray is the first and only FDA-approved nasal spray version of naloxone, a medication that can rapidly reverse the effects of opioids and restore breathing to a person experiencing an opioid overdose. This product has been widely recognized as a significant contributor to opioid overdose reversal efforts, being highly effective and easy to use by both medical professionals and laypersons.
Beyond Narcan Nasal Spray, Opiant Pharmaceuticals is also developing other opioid antagonist products, such as intranasal nalmefene, a drug with a potentially longer duration of action compared to naloxone. The company aims to provide a comprehensive range of life-saving opioid overdose treatments to meet the diverse needs of patients and healthcare providers.
Furthermore, Opiant Pharmaceuticals has explored various novel drug candidates targeting substance use disorder and addiction. These include OPNT003, which is being developed for the treatment of binge eating disorder, and OPNT001, which is being investigated for reducing the craving and reward response associated with stimulant use disorder.
In addition to its research and development activities, Opiant Pharmaceuticals actively engages in collaborations with other organizations to advance its mission. The company has partnered with government agencies, including the National Institutes of Health (NIH), to secure funding and support for its research programs. It has also entered into licensing agreements with pharmaceutical companies to expand the availability of its products across geographies.
Overall, Opiant Pharmaceuticals Inc. is a leading specialty pharmaceutical company dedicated to developing innovative treatments for addiction and drug overdose. With a strong focus on opioid antagonist therapies, the company strives to make a positive impact in addressing the global opioid crisis and improving the lives of individuals affected by substance use disorders.
Opiant Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of innovative treatments for addiction and substance use disorders. Its product pipeline is primarily centered on addressing the urgent need for therapies that can mitigate the effects of opioid overdoses and other substance abuse conditions.
Segments
1. Acute Interventions:
- This segment primarily includes products designed for the immediate management of drug overdoses, with a strong emphasis on opioid overdose. The goal here is to provide rapid, effective interventions that can save lives in critical situations.
2. Chronic Treatment:
- Products aimed at long-term management of addiction and substance use disorders fall under this category. These treatments are designed to help individuals transition from acute situations and maintain sobriety over time, addressing the underlying factors of addiction.
3. Research and Development:
- Opiant invests heavily in R&D, focusing on innovative treatment modalities for addiction. This includes not only pharmacological interventions but also potential combination therapies that could enhance therapeutic outcomes.
Products
1. Nasal Naloxone (Opiant’s flagship product):
- Opiant has developed a nasal spray formulation of naloxone, a well-known opioid antagonist used to reverse opioid overdoses rapidly. This formulation is designed to be easy to use and suitable for emergency situations, making it accessible for individuals in distress as well as first responders. The nasally administered dosage form ensures prompt absorption and rapid onset of action, vital in overdose scenarios.
2. Development Pipeline:
- Opiant has several products under development which focus on various aspects of addiction treatment:
- OPNT003: A potential treatment for the management of alcohol use disorder and other related benefits, leveraging existing therapies to improve outcomes for patients.
- Other Programs: These may include novel formulations of existing drugs or entirely new chemical entities aimed at different pathways in addiction treatment or management of mental health conditions correlated with substance use.
3. Collaborative Efforts:
- The company is often engaged in partnerships and collaborations with other pharmaceutical companies and institutions which help in the co-development of new treatments or in the refinement of existing ones to enhance their effectiveness and market reach.
Services
1. Education and Support Programs:
- Opiant also focuses on developing educational materials and support programs aimed at healthcare providers, patients, and caregivers. This can include information concerning the risks and treatment of substance disorders, the appropriate use of naloxone, and supportive resources for those affected by addiction.
2. Market Access and Distribution:
- The company works on establishing effective distribution channels to ensure that its products are accessible to those in need. This includes collaborating with healthcare systems, pharmacies, and emergency service organizations to facilitate the prompt availability of their treatments in critical situations.
3. Clinical Trials and Research Initiatives:
- In line with their commitment to research, Opiant also engages in clinical trials to gather data on the efficacy and safety of their products. These efforts contribute to advancing scientific understanding and improving treatment methodologies in the fields of addiction and substance abuse.
Overall, Opiant Pharmaceuticals Inc. represents a focused effort within the pharmaceutical industry to tackle the pressing challenges posed by addiction and substance use disorders, offering innovative solutions that encompass both immediate interventions and long-term treatment strategies. The commitment to research, collaborative partnerships, and educational outreach further enhances the impact of their offerings in addressing these critical public health issues.
Segments
1. Acute Interventions:
- This segment primarily includes products designed for the immediate management of drug overdoses, with a strong emphasis on opioid overdose. The goal here is to provide rapid, effective interventions that can save lives in critical situations.
2. Chronic Treatment:
- Products aimed at long-term management of addiction and substance use disorders fall under this category. These treatments are designed to help individuals transition from acute situations and maintain sobriety over time, addressing the underlying factors of addiction.
3. Research and Development:
- Opiant invests heavily in R&D, focusing on innovative treatment modalities for addiction. This includes not only pharmacological interventions but also potential combination therapies that could enhance therapeutic outcomes.
Products
1. Nasal Naloxone (Opiant’s flagship product):
- Opiant has developed a nasal spray formulation of naloxone, a well-known opioid antagonist used to reverse opioid overdoses rapidly. This formulation is designed to be easy to use and suitable for emergency situations, making it accessible for individuals in distress as well as first responders. The nasally administered dosage form ensures prompt absorption and rapid onset of action, vital in overdose scenarios.
2. Development Pipeline:
- Opiant has several products under development which focus on various aspects of addiction treatment:
- OPNT003: A potential treatment for the management of alcohol use disorder and other related benefits, leveraging existing therapies to improve outcomes for patients.
- Other Programs: These may include novel formulations of existing drugs or entirely new chemical entities aimed at different pathways in addiction treatment or management of mental health conditions correlated with substance use.
3. Collaborative Efforts:
- The company is often engaged in partnerships and collaborations with other pharmaceutical companies and institutions which help in the co-development of new treatments or in the refinement of existing ones to enhance their effectiveness and market reach.
Services
1. Education and Support Programs:
- Opiant also focuses on developing educational materials and support programs aimed at healthcare providers, patients, and caregivers. This can include information concerning the risks and treatment of substance disorders, the appropriate use of naloxone, and supportive resources for those affected by addiction.
2. Market Access and Distribution:
- The company works on establishing effective distribution channels to ensure that its products are accessible to those in need. This includes collaborating with healthcare systems, pharmacies, and emergency service organizations to facilitate the prompt availability of their treatments in critical situations.
3. Clinical Trials and Research Initiatives:
- In line with their commitment to research, Opiant also engages in clinical trials to gather data on the efficacy and safety of their products. These efforts contribute to advancing scientific understanding and improving treatment methodologies in the fields of addiction and substance abuse.
Overall, Opiant Pharmaceuticals Inc. represents a focused effort within the pharmaceutical industry to tackle the pressing challenges posed by addiction and substance use disorders, offering innovative solutions that encompass both immediate interventions and long-term treatment strategies. The commitment to research, collaborative partnerships, and educational outreach further enhances the impact of their offerings in addressing these critical public health issues.